MCM
PBYI icon

MAI Capital Management’s Puma Biotechnology PBYI Stock Holding History

MAI Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.3K Buy
7,558
+7,521
+20,327% +$48.5K ﹤0.01% 2253
2025
Q4 		$221 Buy
+37
New +$196 ﹤0.01% 4020

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

MAI Capital Management's PBYI Position: Q1 2026 in Review

MAI Capital Management increased its Puma Biotechnology (PBYI) stake by 20,327% in Q1 2026, buying an estimated $48.5K and bringing the position to 7,558 shares worth $48.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

MAI Capital Management first reported a position in PBYI in Q4 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • MAI Capital Management held 7,558 shares of Puma Biotechnology worth $48.3K as of Q1 2026.
  • MAI Capital Management bought 7,521 Puma Biotechnology shares in Q1 2026, an estimated $48.5K.
  • Puma Biotechnology made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2253 holding.
  • MAI Capital Management first reported a position in Puma Biotechnology in Q4 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.